Drug Device Combination—a High Growth Market” focuses on drug-device combinations that can be chemically or physically united or co-packaged as separate, cross-labeled products.
In the next five years, the market is expected to grow at an annual rate of 11.8 percent, reaching $10.6 billion, the report says.
The drug-eluting stents market is the largest segment in the drug-device combination market.
Cardiovascular applications make up about 64 percent of the drug-device combination market, and it is further broken down into stent grafts, coronary stents and peripheral vascular stents.
However, it is the smaller market of antimicrobial catheters that offers the highest growth potential for the overall market in the next five years.
Though coronary stents have the highest market share, peripheral vascular stents are expected to have the highest growth rate until 2014. The fastest-growing macro-market of antimicrobial catheters is segmented into micro-markets such as urological catheter, cardiovascular catheter, peripherally inserted central catheter, oximetry catheter, thermodilution catheter and wound-drainage catheter.
Closed-loop glucose monitor and insulin pumps also are expected to record a high growth rate until 2014.
Two major segments, steroid eluting electrodes and photodynamic therapy, are estimated to see the slowest growth rate due to a slow development of new products in these markets. The challenges crippling the growth of the market in the future are expected to be issues involved in cross-industry partnerships, jurisdiction issues, patient safety and interoperability issues. For more information about the report, visit www.researchandmarkets.com.